Cargando…

Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia

Preeclampsia is one of the most serious complications of pregnancy. Currently there are no medical treatments. Given placental oxidative stress may be an early trigger in the pathogenesis of preeclampsia, therapies that enhance antioxidant pathways have been proposed as treatments. Melatonin is a di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hannan, Natalie J., Binder, Natalie K., Beard, Sally, Nguyen, Tuong-Vi, Kaitu’u-Lino, Tu’uhevaha J., Tong, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894956/ https://www.ncbi.nlm.nih.gov/pubmed/29641523 http://dx.doi.org/10.1371/journal.pone.0187082

Ejemplares similares

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
por: Hannan, Natalie J., et al.
Publicado: (2017)

Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta
por: Brownfoot, Fiona C., et al.
Publicado: (2016)

Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2018)

Investigating the Effects of Atrial Natriuretic Peptide on the Maternal Endothelium to Determine Potential Implications for Preeclampsia
por: Binder, Natalie K., et al.
Publicado: (2023)

Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease
por: de Alwis, Natasha, et al.
Publicado: (2022)

Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia
por: Binder, Natalie K., et al.
Publicado: (2021)

Clinical tools and biomarkers to predict preeclampsia
por: MacDonald, Teresa M, et al.
Publicado: (2021)

Associations Between Soluble fms‐Like Tyrosine Kinase‐1 and Placental Growth Factor and Disease Severity Among Women With Preterm Eclampsia and Preeclampsia
por: Hastie, Roxanne, et al.
Publicado: (2022)

Serum Collected from Preeclamptic Pregnancies Drives Vasoconstriction of Human Omental Arteries—A Novel Ex Vivo Model of Preeclampsia for Therapeutic Development
por: Fato, Bianca R., et al.
Publicado: (2022)

Placental galectin-3 is reduced in early-onset preeclampsia
por: Kandel, Manju, et al.
Publicado: (2022)

NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast
por: de Alwis, Natasha, et al.
Publicado: (2021)

ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia
por: Pritchard, Natasha, et al.
Publicado: (2018)

Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin
por: Whigham, Carole-Anne, et al.
Publicado: (2019)

A comparison of sample collection methods for quantifying cell-free fetal neurodevelopment transcripts in amniotic fluid
por: Hui, Lisa, et al.
Publicado: (2016)

The Regulation of Endothelin-1 in Pregnancies Complicated by Gestational Diabetes: Uncovering the Vascular Effects of Insulin
por: Fato, Bianca R., et al.
Publicado: (2023)

MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia
por: Whigham, Carole-Anne, et al.
Publicado: (2020)

Therapeutic interventions: The importance of including diseased and healthy samples in preclinical studies
por: Tu'uhevaha J., Kaitu'u-Lino
Publicado: (2019)

Actions of Esomeprazole on the Maternal Vasculature in Lean and Obese Pregnant Mice with Impaired Nitric Oxide Synthesis: A Model of Preeclampsia
por: de Alwis, Natasha, et al.
Publicado: (2022)

Paternal Expressed Gene 10 (PEG10) is decreased in early-onset preeclampsia
por: Baird, Lydia, et al.
Publicado: (2023)

MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2012)

Placental Growth Factor Is Secreted by the Human Endometrium and Has Potential Important Functions during Embryo Development and Implantation
por: Binder, Natalie K., et al.
Publicado: (2016)

Measuring circulating miRNAs in early pregnancy could identify fetuses’ destined to undergrow and be at increased risk of stillbirth
por: Tong, Stephen, et al.
Publicado: (2020)

The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health
por: de Alwis, Natasha, et al.
Publicado: (2022)

A Bioplex Analysis of Cytokines and Chemokines in First Trimester Maternal Plasma to Screen for Predictors of Miscarriage
por: Hannan, Natalie J., et al.
Publicado: (2014)

Serum Concentrations of Soluble Flt-1 Are Decreased among Women with a Viable Fetus and No Symptoms of Miscarriage Destined for Pregnancy Loss
por: Kaitu'u-Lino, Tu'uhevaha J., et al.
Publicado: (2012)

Circulating Chemerin Is Elevated in Women With Preeclampsia
por: Bartho, Lucy A, et al.
Publicado: (2023)

Trophoblast-Targeted Nanomedicine Modulates Placental sFLT1 for Preeclampsia Treatment
por: Li, Lei, et al.
Publicado: (2020)

PSG7 and 9 (Pregnancy‐Specific β‐1 Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia
por: Kandel, Manju, et al.
Publicado: (2022)

Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth
por: Arman, Bridget M., et al.
Publicado: (2023)

Placental OLAH Levels Are Altered in Fetal Growth Restriction, Preeclampsia and Models of Placental Dysfunction
por: de Alwis, Natasha, et al.
Publicado: (2022)

DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia
por: de Alwis, Natasha, et al.
Publicado: (2021)

Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks’ gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study
por: MacDonald, Teresa M., et al.
Publicado: (2018)

Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
por: Bartho, Lucy A., et al.
Publicado: (2023)

Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy
por: Gurnadi, Jeffry Iman, et al.
Publicado: (2015)

Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction
por: Brownfoot, Fiona C., et al.
Publicado: (2019)

Evaluation of ADAM-12 as a Diagnostic Biomarker of Ectopic Pregnancy in Women with a Pregnancy of Unknown Location
por: Horne, Andrew W., et al.
Publicado: (2012)

Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker
por: Cruickshank, Tess, et al.
Publicado: (2021)

RNAi Modulation of Placental sFLT1 for the Treatment of Preeclampsia.
por: Turanov, Anton A., et al.
Publicado: (2018)

Oxidative and Inflammatory Imbalance in Placenta and Kidney of sFlt1-Induced Early-Onset Preeclampsia Rat Model
por: Santana-Garrido, Álvaro, et al.
Publicado: (2022)

Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and Placental Growth Factor (PlGF) in Preeclampsia among High Risk Pregnancies
por: Powers, Robert W., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ei8bj1h4aqijig3gs7at1lhjdk